BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 41 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q1 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $159 | -94.8% | 796 | -46.0% | 0.00% | – |
| Q2 2023 | $3,039 | -37.6% | 1,475 | 0.0% | 0.00% | – |
| Q1 2023 | $4,868 | +66.7% | 1,475 | -17.2% | 0.00% | – |
| Q4 2022 | $2,921 | -58.3% | 1,781 | -32.4% | 0.00% | – |
| Q3 2022 | $7,000 | 0.0% | 2,634 | 0.0% | 0.00% | – |
| Q2 2022 | $7,000 | -61.1% | 2,634 | -40.1% | 0.00% | -100.0% |
| Q4 2021 | $18,000 | -33.3% | 4,399 | -46.8% | 0.00% | 0.0% |
| Q3 2021 | $27,000 | -25.0% | 8,269 | -12.4% | 0.00% | 0.0% |
| Q2 2021 | $36,000 | 0.0% | 9,444 | -0.1% | 0.00% | 0.0% |
| Q1 2021 | $36,000 | – | 9,455 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 242,850 | $923,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 241,500 | $918,000 | 0.13% |
| Weaver Consulting Group | 48,881 | $186,000 | 0.10% |
| Tibra Equities Europe Ltd | 87,000 | $331,000 | 0.10% |
| Ikarian Capital, LLC | 293,200 | $1,115,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 60,238 | $229,000 | 0.03% |
| Ergoteles LLC | 124,329 | $472,000 | 0.01% |
| CFO4Life Group, LLC | 12,003 | $46,000 | 0.01% |
| HighPoint Advisor Group LLC | 17,033 | $65,000 | 0.01% |
| BOOTHBAY FUND MANAGEMENT, LLC | 32,836 | $125,000 | 0.00% |